When did Bioventus report Q1 2026 earnings?

Bioventus (BVS) reported Q1 2026 earnings on May 6, 2026 before market open.

What were Bioventus's Q1 2026 revenue and EPS?

Bioventus reported revenue of $132.1M and eps of $0.15 for Q1 2026.

Did Bioventus beat estimates in Q1 2026?

Revenue beat the consensus estimate of $129.9M by $2.2M. EPS beat the consensus estimate of $0.09 by $0.06.

How did Bioventus's Q1 2026 results compare year-over-year?

Compared to the same quarter a year prior, revenue grew 6.6% from $123.9M a year earlier and eps grew 87.5% from $0.08.

Where can I find Bioventus's Q1 2026 SEC filings?

You can read the 8-K earnings release (0001665988-26-000026) and the 10-Q periodic report (0001665988-26-000027) directly on SEC EDGAR. The filing index links above go to sec.gov.

Bioventus BVS Q1 2026 earnings

Reported May 6, 2026 · Before market open

Revenue$132.1MBeat by $2.2M

EPS$0.15Beat by $0.06

Revenue estimate$129.9M

EPS estimate$0.09

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$155.6M

EPS estimate$0.22

Financials

Q1 2026

Income statement

See full

Revenue$132.1M+6.6%

Gross profit$90.8M+9.3%

Operating income$8.4M+72.8%

Net income$3.1M+218%

EPS (diluted)$0.04+200%

Balance sheet

See full

Cash & equivalents$35.8M+57.2%

Total debt$288.4M-21.2%

Total equity$188.9M+27.5%

Total assets$650.5M-5.9%

Cash flow

See full

Operating cash flow$8.9M+146%

CapEx$574.0K-30.5%

Free cash flow$8.4M+141%

Valuation & ratios

Valuation

as of 07/28/26

See full

Market cap$843.46M+94.7%

Enterprise value$1.1B+44.0%

P/E29.6×—

P/S1.5×+0.7×

Profitability

See full

Gross margin68.7%+1.2pp

Operating margin10%—

Net margin4.9%+3.2pp

FCF margin17.5%+13.2pp

Returns & leverage

See full

Return on equity16.9%+10.9pp

Debt / equity1.5×-0.9×

Current ratio1.7×+0.3×

Segments

By product

See full

Pain Treatments$63.4M+7.7%

Surgical Solutions$48.0M+6.2%

Restorative Therapies$20.6M+4.6%

By segment

See full

U.S. Segment$116.4M+5.4%

International Segment$15.6M+17.1%

Versus estimates

Revenue

Q1 2026$132.1MBeat by $2.2M

Q4 2025$157.9MBeat by $3.0M Q3 2025$138.7MMiss by $17.1M Q2 2025$147.7MBeat by $8.9M Q1 2025$123.9MMiss by $22.0M Q4 2024$153.6MBeat by $29.1M

Diluted EPS

Q1 2026$0.15Beat by $0.06

Q4 2025$0.24Beat by $0.02 Q3 2025$0.15Miss by $0.07 Q2 2025$0.21Miss by $0.01 Q1 2025$0.08Beat by $0.02 Q4 2024$0.15Beat by $0.07

Ask the moment Bioventus reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Bioventus report Q1 2026 earnings?: Bioventus (BVS) reported Q1 2026 earnings on May 6, 2026 before market open.
What were Bioventus's Q1 2026 revenue and EPS?: Bioventus reported revenue of $132.1M and eps of $0.15 for Q1 2026.
Did Bioventus beat estimates in Q1 2026?: Revenue beat the consensus estimate of $129.9M by $2.2M. EPS beat the consensus estimate of $0.09 by $0.06.
How did Bioventus's Q1 2026 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 6.6% from $123.9M a year earlier and eps grew 87.5% from $0.08.
Where can I find Bioventus's Q1 2026 SEC filings?: You can read the 8-K earnings release (0001665988-26-000026) and the 10-Q periodic report (0001665988-26-000027) directly on SEC EDGAR. The filing index links above go to sec.gov.